SLDB at a glance
Solid Biosciences Inc. (SLDB, SEC CIK 1707502) filed its latest 10-K annual report on March 19, 2026, a 10-Q quarterly report on November 4, 2026, an 8-K current report on August 6, 2026 and Form 4 insider filings as recently as October 26, 2026. SignalX summarizes each filing with AI and tracks the company's insider trades and institutional holders.
- As of September 30, 2026, 26 institutional investment managers tracked by SignalX reported holding Solid Biosciences Inc. (SLDB) shares worth $224.6 million in 13F-HR filings.
- The most recent insider open-market sale reported on Form 4 was by Brooks Gabriel on October 19, 2026 of 4,374 shares at $5.62 per share.
- In the last 90 days, SLDB insiders reported 0 open-market purchases ($0) and 1 open-market sale ($25K) on Form 4, a net sale of $25K.
Source: SEC EDGAR (XBRL financial data, 13F-HR and Form 4 filings).
- Insiders · 90 days
- 0 buys · 1 sell
- Net −$25K
- 13F holders
- 26 funds
- $224.6M · +0 vs prior quarter
- Latest 8-K
- Aug 6, 2026
- Item 8.01
AI 10-Q Quarterly Report Analysis
Latest 10-Q, quarter ended Sep 30, 2026
Management Discussion & Analysis
- Revenue $0, no commercial product revenue, unchanged from prior-year quarter
- Net loss $53.9M vs $45.8M YoY, operating expenses $57.7M vs $48.1M
- Best-performing program SGT-212, R&D expense $4.4M, up 144.3% YoY
- Cash, equivalents and securities $348.9M, sufficient into first half of 2028
- Operating cash use $145.4M, financing provided $303.4M, including $226.3M private placement proceeds
Risk Factors
- Newly added regulatory risk: evolving FDA trial-design expectations may require randomized trials, larger populations or longer follow-up
- Most material regulatory update: FDA workforce reductions and proposed HHS budget cuts could delay IND and BLA reviews
- Operational risk: transient-transfection manufacturing remains complex, with capacity constraints potentially delaying clinical supply
- Competitive risk: Sarepta’s ELEVIDYS approval and competitors’ Duchenne programs intensify pressure on SGT-003
- Financial risk: cash, cash equivalents and securities expected to fund operations only into the first half of 2028
AI summary of the SLDB 10-Q filed . Generated from the filing text; verify against the original.View on SEC EDGAR10-K vs 10-Q vs 8-K
AI 8-K Current Report Analysis
The most recent material events, by 8-K item
Item 8.01: Other Events
- New prospectus supplement permits up to $200.0 million in additional common-stock sales through Jefferies
- Approximately $85.0 million already raised under the prior supplement, which is now superseded
Item 5.07: Submission of Matters to a Vote of Security Holders
- Shareholders elected Clare Kahn, Adam Stone, and Lynne Sullivan as Class II directors through the 2029 annual meeting
- PricewaterhouseCoopers LLP ratified as independent auditor for fiscal year 2026 with 86.4 million votes for
Item 5.02: Departure/Appointment of Directors or Principal Officers
- Ilan Ganot shifted from Class III to Class I effective April 10, 2026, preserving equal Board-class membership
- Class III director count decreased to three; Class I increased to three
AI summaries of SLDB 8-K current reports filed with the SEC. What 8-K item codes mean
SignalX for SLDB
Don't miss the next SLDB filing
- Alerts as it files. A push when SLDB files an 8-K or an insider trades.
- Fund moves. Which tracked funds opened, added or cut SLDB, by share count.
- Ask anything. An AI agent that reads every SLDB filing and answers with sources.
Recent Insider Transactions (Form 4)
Latest reported trades by officers, directors and 10% owners
| Insider | Type | Date | Shares | Price |
|---|---|---|---|---|
| Brooks Gabriel | Sell | Oct 19, 2026 | 4,374 | $5.62 |
| Brooks Gabriel | M | Oct 18, 2026 | 9,750 | - |
| Brooks Gabriel | M | Oct 18, 2026 | 9,750 | - |
| SMITH IAN F | M | Oct 2, 2026 | 3,440 | - |
| SMITH IAN F | M | Oct 2, 2026 | 3,440 | - |
| Ganot Ilan | A | Oct 1, 2026 | 150,000 | - |
| SMITH IAN F | M | Jul 2, 2026 | 3,440 | - |
| SMITH IAN F | M | Jul 2, 2026 | 3,440 | - |
Financial SummaryXBRL
| Metric | FY2023 | FY2024 | FY2025 |
|---|---|---|---|
| Profitability | |||
| Operating Income | - | -$129.7M | -$179.2M |
| Net Income | -$96.0M | -$124.7M | -$174.3M |
| Balance Sheet | |||
| Total Assets | $164.9M | $188.7M | $232.5M |
| Equity | $126.5M | $137.2M | $180.0M |
| ROE | -75.9% | -90.9% | -96.8% |
| Per Share | |||
| EPS | $-4.83 | $-3.06 | $-1.99 |
| Cash Flow | |||
| Operating CF | -$94.2M | -$100.0M | -$156.3M |
| CapEx | $1.5M | $654K | $1.2M |
Source: XBRL data in Solid Biosciences Inc. (SLDB)'s 10-K filings on SEC EDGAR, in USD. Compare across companies →
13F Fund Holdings: Quarterly Trend
Latest: Q3 2026Aggregate SLDB share value held by 13F filers tracked by SignalX, by quarter.
Quarterly totals table
| Quarter | Funds | Total value |
|---|---|---|
| Q3 2026 | 26 | $224.6M |
| Q2 2026 | 26 | $369.0M |
| Q1 2026 | 26 | $177.4M |
| Q4 2025 | 23 | $101.5M |
| Q3 2025 | 24 | $128.4M |
| Q2 2025 | 23 | $100.2M |
| Q1 2025 | 21 | $43.1M |
| Q4 2024 | 15 | $18.0M |
- JPMorgan Chase & Co+899.8K (+319%)
- Morgan Stanley+898.3K (+352%)
- Franklin Resources+752.8K (+22%)
- Ameriprise Financial+693.0K (+31%)
- Invesco Ltd+177.2K (+124%)
- State Street Corp−852.3K (-20%)
- Citadel Advisors LLC−717.9K (-26%)
- Goldman Sachs Group−445.1K (-28%)
- D.E. Shaw & Co−106.8K (-48%)
- BlackRock−99.0K (-1%)
- Millennium Management+237.6K
- Principal Financial Group+11.9K
- FMR LLC (Fidelity)−6.88M
- Renaissance Technologies LLC−82.1K
Source: 13F-HR filings on SEC EDGAR (aggregated from 184 fund-quarter rows). Reflects only 13F filers tracked by SignalX, not the full institutional ownership universe. How 13F filings work
SLDB filing archive
AI analysis pages for each 10-K, 10-Q and 8-K
10-Q quarterly reports
Latest 2026 SEC Filings: 10-K, 10-Q, 8-K & Form 4
| Form | Filing date | Period | Analysis | SEC |
|---|---|---|---|---|
| 10-Q | Nov 4, 2026 | Sep 30, 2026 | Analysis | |
| 4 | Oct 26, 2026 | - | - | - |
| 4 | Oct 20, 2026 | - | - | - |
| 4 | Oct 6, 2026 | - | - | - |
| 10-Q | Aug 6, 2026 | Jun 30, 2026 | Analysis | |
| SC 13G | Aug 6, 2026 | - | - | |
| 8-K | Aug 6, 2026 | - | Analysis | - |
| SC 13G | Jul 30, 2026 | - | - | |
| 4 | Jul 7, 2026 | - | - | - |
| 4 | Jun 11, 2026 | - | - | - |
| 4 | Jun 11, 2026 | - | - | - |
| 4 | Jun 11, 2026 | - | - | - |
| 4 | Jun 11, 2026 | - | - | - |
| 4 | Jun 11, 2026 | - | - | - |
| 4 | Jun 11, 2026 | - | - | - |
| 4 | Jun 11, 2026 | - | - | - |
| 4 | Jun 11, 2026 | - | - | - |
| 4 | Jun 11, 2026 | - | - | - |
| 8-K | Jun 10, 2026 | - | Analysis | |
| 10-Q | May 12, 2026 | Mar 31, 2026 | Analysis | |
| 4 | Apr 21, 2026 | - | - | - |
| 4 | Apr 21, 2026 | - | - | - |
| 4 | Apr 21, 2026 | - | - | - |
| 4 | Apr 21, 2026 | - | - | - |
| 4 | Apr 21, 2026 | - | - | - |
Related Health Care companies
- FDMT · 4D Molecular Therapeutics, Inc.Biological Products, (No Diagnostic Substances)
- ADPT · Adaptive Biotechnologies CorpBiological Products, (No Diagnostic Substances)
- ADMA · ADMA BIOLOGICS, INC.Biological Products, (No Diagnostic Substances)
- ALEC · Alector, Inc.Biological Products, (No Diagnostic Substances)
- ALLO · Allogene Therapeutics, Inc.Biological Products, (No Diagnostic Substances)
- AMGN · AmgenBiological Products, (No Diagnostic Substances)
- AVXL · ANAVEX LIFE SCIENCES CORP.Biological Products, (No Diagnostic Substances)
- APGE · Apogee Therapeutics, Inc.Biological Products, (No Diagnostic Substances)
SLDB SEC filings: frequently asked questions
Are SLDB insiders buying or selling?
In the last 90 days, Solid Biosciences Inc. (SLDB) officers, directors and 10% owners reported no open-market purchases and 1 open-market sale worth $24,582 by 1 insider on Form 4. Many insider sales are pre-planned or for taxes, so purchases usually carry more information.
Which institutions hold SLDB stock?
As of September 30, 2026, the largest Solid Biosciences Inc. (SLDB) holders among the 13F filers tracked by SignalX were BlackRock ($49.4 million), Vanguard Capital Management LLC ($28.7 million), Franklin Resources ($27.3 million), State Street Corp ($24.0 million), Ameriprise Financial ($21.1 million). 13F-HR reports are filed up to 45 days after each quarter ends.
What did SLDB report in its latest 8-K?
Solid Biosciences Inc. (SLDB) filed an 8-K on August 6, 2026 reporting Item 8.01 (Other Events). New prospectus supplement permits up to $200.0 million in additional common-stock sales through Jefferies.
What are the latest SLDB SEC filings?
Solid Biosciences Inc. (SLDB) filed its latest 10-K annual report on March 19, 2026, a 10-Q quarterly report on November 4, 2026, an 8-K current report on August 6, 2026 and a Form 4 insider filing on October 26, 2026.
What is SLDB's SEC CIK number?
Solid Biosciences Inc. (SLDB)'s SEC Central Index Key (CIK) is 1707502. EDGAR lists every SLDB filing under that number.
Ask anything about SLDB
The research agent reads SLDB's filings, financials, insider trades and 13F holders, then answers with sources.